Data from AstraZeneca’s (LSE: AZN) BORA trial, a Phase III extension study of Fasenra (benralizumab), show the sustained efficacy of the therapy as an add-on maintenance treatment for certain severe eosinophilic asthma patients.
The London-listed drugmaker will present the data at a late-breaking oral session today, at the European Respiratory Society (ERS) International Congress 2018 in Paris.
The results show that patients given Fasenra for an additional 56 weeks maintained improvements in efficacy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze